Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia [NA]

View source ↗

Summary

Clinical trial update for JY231 Injection studying its use in relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukemia; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• JY231

Snippet

Sponsor: Shenzhen Genocury Biotech Co., Ltd. | Conditions: B-NHL, B-ALL | NA | Status: RECRUITING